The world needs to know the facts as to how the FDA "protects" the public health by assuring the safety, effectiveness, and security of human drugs and biological products for human use. Recent uproar has surfaced over the FDA's approval process on the unproven Duchenne Muscular Dystrophy (DMD) drug, Exondys 51 (Sarepta Therapeutics, Cambridge, MA, USA), but what many people do not know are the unlawful events that occurred nearly two decades ago on a proven and promising treatment for DMD.
Mammalian evolution over 160 million years witnesses their unique ability to fuse during muscle development and regeneration. Implanted myoblasts naturally fuse among themselves to form genetically normal muscle fibers to replenish dead fibers. They also fuse with dystrophic muscle fibers, inserting their nuclei that carry the normal genome to produce genetic complementation repair. As such, MTT is a somatic cell therapy and a gene therapy, or more correctly, a genome therapy with nuclei transfer.
Development of Myoblast Transfer Therapy
First published in Lancet on July 14, 1990 , MTT is the world's first human gene therapy to have replenished dystrophin, a structural protein not produced in DMD muscles [1] . That was the dawn of Regenerative Medicine in the field of somatic cell therapy. If replenishing dystrophin is all that it takes to cure DMD and to be granted FDA Biologic License Approval (BLA), my team had achieved that in the year 1990, if not, then in the years ensuing. We even demonstrated that dystrophin persisted in the same muscle at six years after MTT [2] . The work came after 15 years of basic research supported by 11 years of top-priority NIH (National Institutes of Health) grants.
The organization that I founded, Cell Therapy Research Foundation (CTRF), had requested granting of a Treatment IND (Investigational New Drug) in 1998, but it was turned down. FDA admitted that functional data had demonstrated efficacy, but had question about histology. It is not difficult to see histologic efficacy in our publications dated before November 1998 [1] - [11] . In reality, functional improvement in muscle contraction should be the primary end point for these clinical trials and not dystrophin production alone. In the lengthy, make-believe "483"s that described logistic rather than scientific deficiencies, there was not a statement describing death or permanent severe adverse reaction of any trial subject. There was no statement describing dishonesty or forgery. Our response to the "483"s were simply ignored. CTRF went bankrupt after FDA would not allow the study to move forward.
The Controversy
In 2016, US FDA approved Exondys 51 developed by Sarepta Therapeutics as the first DMD drug. They approved Exondys 51 on fast track, priority review, and orphan drug designation. Accelerated approval made this drug available to patients based on initial data. The aftermath was not pleasant. Open Journal of Regenerative Medicine
The FDA News Release on September 19, 2016 documented that, "A clinical benefit of Exondys 51, including improved motor function, has not been established" and that, "The most common side effects reported by participants taking Exondys 51 in the clinical trials were balance disorder and vomiting" (Attachment 1) [12] . The Associated Press on the same day called Exondys 51 "the largely unproven medication." [13] In the following months, media outlets and reputable individuals lambasted the FDA's egregious decision making [14] where we continued to have breakthroughs by successfully treating cancer tumors, Type II diabetes, heart failure and muscular dystrophy using MTT in human trials [31] [32] [33] . MTT technology is on the verge of a worldwide boom and CTI is now accepting foreign patients for the treatment of DMD.
The Rise, Fall and Return of MTT

Closing Remarks
As an accomplished scientist who has spent 46 years in muscle regeneration, I do not believe any drug of biochemical nature can replenish the estimated 50% muscle fiber loss when DMD boys go into wheelchairs and the estimated 80% loss when they suffocate. Dystrophin is a large structural protein and its gene The most common side effects reported by participants taking Exondys 51 in the clinical trials were balance disorder and vomiting.
The FDA granted Exondys 51 fast track designation, which is a designation to facilitate the development and expedite the review of drugs that are intended to treat serious conditions and that demonstrate the potential to address an unmet medical need. It was also granted priority review and orphan drug designation.
Priority review status is granted to applications for drugs that, if approved, would be a significant improvement in safety or effectiveness in the treatment of a serious condition. Orphan drug designation provides incentives such as clinical trial tax credits, user fee waiver and eligibility for orphan drug exclusivity to assist and encourage the development of drugs for rare diseases.
The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.
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